Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rock1tm1Leiw mutation
(0 available);
any
Rock1 mutation
(57 available)
|
|
|
mortality/aging
|
|
• about 50 to 60% of embryos die before implantation or early postimplantation
|
cardiovascular system
|
|
• homozygotes undergoing transverse aortic banding to induce concentric cardiac hypertrophy show a smaller increase in cardiac fibrosis and reduced expression of a variety of extracellular matrix proteins and fibrogenic cytokines at 3 weeks after banding than wild-type, however hypertrophic responses are not impaired and cardiac dimension and contractile function are preserved
|
|
|
• exhibit about a 20% increase in heart rate after induction of pressure overload
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rock1tm1Leiw mutation
(0 available);
any
Rock1 mutation
(57 available)
|
|
|
mortality/aging
|
|
• about 30% of embryos die before implantation or early postimplantation
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Leprdb mutation
(17 available);
any
Lepr mutation
(121 available)
Rock1tm1Leiw mutation
(0 available);
any
Rock1 mutation
(57 available)
|
|
|
renal/urinary system
|
N |
• mice treated with streptozotocin to induce diabetes do not exhibit podocyte loss unlike similarly treated Leprdb homozygotes
|
|
|
• mice treated with streptozotocin to induce diabetes exhibit glomerular apoptosis but not as much as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes but not as much as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes but not as much as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
homeostasis/metabolism
growth/size/body
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
|
|
• in mice treated with streptozotocin to induce diabetes as in similarly treated Leprdb homozygotes
|
cellular
|
|
• mice treated with streptozotocin to induce diabetes exhibit glomerular apoptosis but not as much as in similarly treated Leprdb homozygotes
|
|
|
• mice treated with streptozotocin to induce diabetes exhibit mitochondrial reactive oxygen species production but not as much as in similarly treated Leprdb homozygotes
• mice treated with streptozotocin to induce diabetes exhibit mitochondrial fission but not as much as in similarly treated Leprdb homozygotes
|
|
|
• mice treated with streptozotocin to induce diabetes exhibit mitochondrial reactive oxygen species production but not as much as in similarly treated Leprdb homozygotes
|
Analysis Tools